Merck
New C. difficile Guidelines Recommend New Treatment, Testing Protocols
CDI affects nearly 500,000 Americans every year, resulting in 15,000 to 30,000 deaths and costing more than $4.8 ...
FEBRUARY 26, 2018
FDA Approves Second Biosimilar of Remicade
Renlexis, a TNF blocker, will be indicated for the treatment of adult and pediatric Crohn’s disease, adult ...
APRIL 24, 2017
The FDA Approves Zepatier To Treat HCV
Zepatier achieves SVR12 in a broad range of HCV patients, including those with compensated cirrhosis, renal ...
JANUARY 29, 2016
Load more